FDA Rejects uniQure’s Huntington’s Gene Therapy Pathway, Demands Larger Trial
Event summary
- uniQure received final FDA meeting minutes on January 30, 2026, rejecting its proposed regulatory pathway for AMT-130 based on Phase I/II data.
- The FDA demanded a prospective, randomized, double-blind, sham surgery-controlled Phase III study instead.
- uniQure plans to request a Type B meeting with the FDA in Q2 2026 to discuss alternative study designs.
The big picture
The FDA’s demand for a more rigorous trial design reflects growing scrutiny over gene therapy approvals, particularly for rare neurodegenerative diseases. This setback could delay AMT-130’s market entry by years, testing uniQure’s ability to sustain development momentum amid rising costs and competitive pressures in the Huntington’s disease space.
What we're watching
- Regulatory Flexibility
- Whether the FDA will apply its stated commitment to regulatory flexibility for AMT-130 despite rejecting current data.
- Trial Design Challenges
- The complexity and timeline of designing a sham surgery-controlled Phase III study for Huntington’s disease.
- Development Costs
- The financial impact of conducting an additional large-scale trial on uniQure’s resources and funding strategy.
Our editorial coverage:
Related topics